

-Translation -

Minute of the Annual General Meeting of Shareholders 2026
Bangkok Genomics Innovation Public Company Limited

Date, Time and Place

The meeting was held on April 28, 2026, at 10:30 hours, via Electronic Meeting.

Prof. Dr. Thosaporn Sirisumphand, Chairman of the Board, acting as the Chairman of the Meeting (“Chairman”). The Chairman welcomed the shareholders, proxies, directors, executives, and all attendees to the meeting and informed the meeting that, at the time of the meeting commencement, there were 36 shareholders attending in person and by proxy, representing a total of 435,524,103 shares, equivalent to 72.5874% of the Company’s total issued shares of 600,000,000 shares. The quorum was therefore constituted in accordance with the Company’s Articles of Association. The Chairman then declared the 2026 Annual General Meeting of Shareholders open.

Before proceeding to the meeting agenda, the Chairman assigned Ms.Achiraya Rabiabnaveenurak to act as the master of ceremonies and meeting moderator. The moderator then introduced the directors, executives, and auditors as follows:

Directors attending the meeting in the conference room

- | | | |
|------------------------|----------------|---|
| 1. Prof. Dr. Thosaporn | Sirisumphand | Independent Director and Chairman of the Board of Directors |
| 2. Mr. Vichate | Tantiwanich | Independent Director and Chairman of the Audit Committee |
| 3. Dr. Jedsada | Chokdamsongsuk | Independent Director and member of the Audit Committee |
| 4. Dr. Vichya | Kreangam | Independent Director and member of the Audit Committee |
| 5. Mr. Goanpot | Asvinvichit | Director and Chirman of Executive Committee |
| 6. Mr. Preecha | Laohapongchana | Director and member of Executive Committee |
| 7. Dr. Saowalak | Dansakul | Executive Committee and Chief Executive Officer |

Directors attending the meeting via the electronic channel

- | | | |
|----------------|------|--|
| 8. Mr. Xiaohan | Wang | Executive Committee and Deputy Chief Executive Officer |
| 9. Mr. Sujie | Cao | Director and Executive Committee |
| 10. Mr. Zongze | Wu | Director |

กรรมการบริษัทที่ไม่สามารถเข้าร่วมประชุม

- | | | |
|--------------|----|----------|
| 11. Dr. Ning | Li | Director |
|--------------|----|----------|

Note The director was unable to attend the shareholders’ meeting due to an important personal commitment.

-Translation -

The Company has a total of 11 directors, of whom 10 directors attended the meeting today, representing 90.91% of the total number of directors.

Management attending the meeting in the conference room

- | | | |
|-----------------|------------|-----------------------|
| 1. Mr. Kittikun | Rodrangnok | Chief Finance Officer |
|-----------------|------------|-----------------------|

Auditors attending the meeting via the electronic channel

- | | | |
|-------------------|---------------|---|
| 1. Mr. Chaiyakorn | Aunpitipongsa | Managing Director, Dr. Virach & Associates Office Co., Ltd. |
| 2. Mr. Tirawot | Laonapakul | Director of Audit, Dr. Virach & Associates Office Co., Ltd. |

Other

- | | | |
|---------------------|---------|---------------------|
| 1. Ms. Puttarawicha | Mhankid | Company's secretary |
|---------------------|---------|---------------------|

Additionally, IR Network Co., Ltd., a public relations consulting firm, was present at the meeting. Mr. Supotch Onlamoon was responsible for verifying shareholder registrations and counting the votes.

Before proceeding to consider each agenda item of the meeting, the Chairman invited Ms.Achiraya Rabiabnaveenurak to explain the meeting procedures, the voting rules, and the details of each agenda item to the attendees. The company utilized the online meeting services provided by Affinity Relation Co., Ltd. The key points were as follows:

1. In each agenda item, all participants may vote according to the number of shares they hold or are authorized to represent by proxy, with one share equaling one vote. If any shareholder has a special interest in a particular matter, that shareholder is not entitled to vote on that matter, except in the case of voting for director appointments.
2. Shareholders may not divide their shares by granting proxies to multiple persons in order to split their votes. A shareholder must grant a proxy for the full number of shares held and cannot authorize only a portion, except in the case of a Custodian appointed by a foreign investor as the securities depository and manager, in accordance with Proxy Form C.
3. For those using Proxy Forms B and C, where the grantor has already indicated their voting instructions, the company has recorded the votes according to the grantor's intention.
4. The voting results for each agenda item will be announced immediately after the vote counting for that item is completed.
5. In the event of a tie vote, the Chairman shall cast an additional vote to make the final decision.

-Translation -

For details regarding the voting procedures, the steps are as follows:

1. If any shareholder wishes to vote “Disagree” or “Abstain,” please click on the icon of a person on the left side of the screen. The meeting agenda will appear, along with buttons to select “Agree,” “Disagree,” or “Abstain.”
2. Please click on only one of the voting options according to your intention: Agree, Disagree, or Abstain.
3. The time allotted for voting on each agenda item is 1 minute. If voting has not yet closed, shareholders may change their vote at any time until the system closes the voting.
4. The system will display the status of the most recent vote selected.
5. If a shareholder or proxy holder does not press any voting button, the company will consider that person as having voted “Agree” on the agenda item.
6. Once the company announces the closure of the voting system, shareholders or proxy holders will no longer be able to vote on that particular agenda item. The voting status button will indicate that voting is no longer available.
7. The vote count for each agenda item will include only the votes of those who selected “Disagree” or “Abstain.” These votes will be subtracted from the total number of votes of the attendees. The remaining votes will be counted as “Agree” votes in favor of the agenda item.
8. After voting is completed, you may click on the person icon again to collapse the left-hand menu and continue participating in the meeting.

The company has recorded the meeting in the form of video media. This process involves the collection, use, and disclosure of personal data, including the voices and video images of all participants, for the purposes of minute-taking, meeting management, and other administrative functions. These actions are conducted in accordance with the Personal Data Protection Act B.E. 2562 (2019) and the laws governing electronic meetings.

In the event that shareholders have any questions during the meeting, the directors and executives will address such questions during the “Q&A” session at the end of the meeting, including clarifications relating to the Management Discussion and Analysis (MD&A).

Thereafter, the meeting moderator proposed that the meeting proceed to consider the following agenda items.

Agenda 1 Chairman Remarks

The Chairman welcomed and thanked the shareholders for attending the Annual General Meeting of Shareholders and informed the meeting of the overall global economic conditions, which remain volatile and uncertain in terms of international trade, affecting the business sector as a whole. Nevertheless, the medical and healthcare industry continues to demonstrate steady growth, driven by increasing demand for healthcare services, preventive care, and support from both the public and private sectors in terms of technology and policy.

-Translation -

In addition, Thailand is facing a declining birth rate trend, which may affect the demand for certain types of medical services in the long term. The Company therefore aims to adjust its strategies and expand its service scope in line with the changing demographic structure, while recognizing opportunities to further develop its genetic and genomic testing business.

During the past year, the Company invested in new technologies and enhanced its testing processes to improve accuracy and efficiency in order to support healthcare demands and advance Precision Medicine initiatives. The Company also continued to develop personnel capabilities and strengthen its competitiveness through internationally recognized technologies. At the same time, the Company aims to expand its service platform to become a comprehensive genomics solutions provider for both public and private healthcare organizations, as well as to establish diversified revenue streams and recurring income from the distribution of reagents and equipment in the long term.

On behalf of the Board of Directors, management, and employees, the Chairman expressed appreciation to the shareholders, customers, business partners, and all stakeholders for their continued support and trust in the Company. The Chairman also reaffirmed the Company's commitment to sustainable business operations, with due consideration for environmental responsibility, efficient resource utilization, and the promotion of public health, in order to achieve stable growth and create long-term value.

The Chairman then opened the session for shareholders to ask questions or comments.

In this regard, shareholders raised certain questions, which the directors and management will address during the "Q&A" session at the end of the meeting, including clarifications relating to the Management Discussion and Analysis (MD&A).

This agenda was for the meeting's acknowledgement, no voting was required. Therefore, it was concluded that the meeting acknowledged the information from the Chairman regarding the Company's operations and direction.

Agenda 2 To consider and adopt the minutes of the Annual General Meeting of Shareholders 2025

The Chairman proposed that the meeting consider and approve the Minutes of the 2025 Annual General Meeting of Shareholders held on 28 April 2025. The Company had delivered a copy of such minutes to the shareholders together with the notice of the meeting and had also published the minutes on the Company's website. The Board of Directors had reviewed the minutes and was of the opinion that they had been accurately and completely recorded in all material respects.

The Chairman then opened the session for shareholders to ask questions or comments.

There were no objections or requests for amendments to the minutes from any shareholders.

-Translation -

The Chairman therefore requested the meeting to consider and approve the Minutes of the Annual General Meeting of Shareholders 2025.

Meeting Resolution The meeting resolved, by a majority vote of the shareholders present and casting their votes, to approve and certify the Minutes of the 2025 Annual General Meeting of Shareholders held on 28 April 2025, with the voting results as follows:

Approve	436,599,203 votes or 100%
Disapprove	0 votes or 0%
Abstain	0 votes

Remark: In this agenda item, an additional 2 shareholders attended the meeting, resulting in a total of 38 shareholders attending the meeting and entitled to vote prior to the resolution on this agenda item, representing a total of 436,599,203 shares.

Agenda 3 To acknowledge the reports of board of directors and operating results for the year ended 31 December 2025

The Chairman informed the meeting that the Board of Directors had prepared the Company's operating results report for the year ended 31 December 2025 for the shareholders' acknowledgment. The Chairman therefore assigned Mr. Kittikun Rodrangnok, Chief Finance Officer, to summarize the overview of the operating results as follows:

For the operating results for the year 2025, the Group continued to maintain steady and sustainable growth, with total operating revenue amounting to THB 379.5 million, representing an increase of THB 41.9 million or 12.4% from the previous year.

The Group's revenue can be divided into two main categories as follows:

1. Revenue from services amounted to THB 267.6 million, representing an increase of 4.3% from the previous year. Although revenue from Non-Invasive Prenatal Testing (NIPT) slightly declined due to market competition during the second and third quarters, the Company was able to achieve significant revenue growth in the fourth quarter as a result of previously implemented strategies. This was also supported by a 65.4% increase in technology service revenue and the commencement of revenue recognition from advanced medical services launched during the current year.

The principal revenue from services continued to be derived from Non-Invasive Prenatal Testing (NIPT), amounting to THB 232.97 million, representing 87.05% of the total service revenue. Meanwhile, revenue from other screening services and technology-related services continued to grow steadily, particularly technology-related services, which increased by 65.38% compared to the previous year.

2. Revenue from sales amounted to THB 111.8 million, representing an increase of 37.9% from the previous year. The key contributing factors included the expansion of the laboratory equipment and specialized reagent markets,

-Translation -

the launch of advanced medical products, the continuous expansion of product lines, and collaborations with both public and private sector partners, all of which received a positive response from the Thai market.

The majority of the sales revenue was derived from the sale of laboratory equipment and reagents, amounting to THB 100.78 million, representing 90.09% of the total sales revenue. In addition, the Company has begun to generate growing revenue from the sale of Advanced Therapy Medicinal Products (ATMPs), which accounted for 8.19% of total sales.

With respect to operating performance, the Group recorded a net profit for the year 2025 of THB 45.33 million, representing a decrease of THB 4.83 million or 9.63% from the previous year. The net profit margin was 11.72%, declining from 14.50% in the previous year, mainly due to the slowdown in revenue from NIPT services during the second and third quarters as a result of market competition. However, the Company was able to recover in the fourth quarter through adjustments to its business strategies, expansion into new markets, and government policies encouraging pregnant women to undergo Down syndrome screening. As a result, net profit in the fourth quarter increased to THB 26.01 million.

The decrease in net profit was partly attributable to higher selling and administrative expenses incurred to support long-term investments. The Company invested in research and development (R&D), the enhancement of information technology systems, and the expansion of operational capabilities to support future business growth.

To provide shareholders with a broader overview of the Company's operations, the Chairman assigned Dr. Saowalak Dansakul, Chief Executive Officer, to present the Company's strategies and operational plans to the meeting as follows:

Section 1 The Company's Service Business

The Company provides genetic testing services covering all stages of life through the use of technology and Clinical Service Solutions, which have continuously served as the Company's core business operations. In 2025, the Company further expanded its services into the area of non-communicable diseases (NCDs) and enhanced its service platform to provide more comprehensive healthcare solutions.

The Company focuses on delivering integrated healthcare services for all age groups, beginning with reproductive health services such as Non-Invasive Prenatal Testing (NIPT) and Carrier Screening, both of which have gained widespread popularity and are extensively provided throughout Thailand.

The Company also provides newborn screening services and in-depth genetic disease diagnostics through Whole Exome Sequencing technology to support the effective diagnosis of rare diseases. In addition, the Company established a Precision Medicine laboratory to support tissue analysis for oncology and infectious disease testing, thereby enhancing diagnostic efficiency and treatment planning.

Furthermore, the Company offers personalized medicine services (Personal Life Medicine or Personal DNA Testing) by utilizing genetic information to support preventive healthcare. Such services include Biological Age testing, Microbiome services, and Nutrigenomics, all of which have attracted increasing interest among wellness-focused customers. The Company also has plans to support the

-Translation -

management of non-communicable diseases (NCDs) through NGS Solutions technology, which can comprehensively support installation and operations in both public and private laboratories.

The Company is committed to developing an integrated healthcare ecosystem covering all stages of life, from prenatal care and disease diagnosis to treatment and long-term healthcare management, through the use of precise medical technologies.

Section 2: Key Developments and Strategic Progress of the Company in 2025

In 2025, the Company achieved several key developments and strategic advancements, encompassing collaborations and projects with both public and private sector organizations to support business expansion and the development of medical technologies.

The Company entered into Memoranda of Understanding (MOUs) and cooperation agreements with several key organizations, including:

- Collaboration with Eisai (Thailand) Marketing Co., Ltd. to enhance Alzheimer's disease screening and treatment services.
- Collaboration with MGI Tech Co., Ltd. for the installation of Next Generation Sequencing (NGS) platforms, including data storage systems and related equipment, to support future expansion in genomics operations.
- Collaboration with the Agricultural Research Development Agency (Public Organization) (ARDA) to support the application of genetic and biotechnology innovations in the agricultural sector.
- Collaboration with the Department of Medical Services to support Down syndrome screening through Non-Invasive Prenatal Testing (NIPT).
- Joint operations with the Faculty of Medicine, Chulalongkorn University, in the development of CAR-T Cell technology, as well as collaborations with government agencies such as the Department of Medical Services and the Department of Medical Sciences in research projects and advanced laboratory testing services, including cooperation in Advanced Therapy Medicinal Products (ATMPs) and Telemedicine projects with relevant organizations.

In addition, the Company increased its investment in Omicsphere Co., Ltd., a subsidiary in which the Company holds shares, to support business expansion and investment in advanced medical technologies. At the same time, Omicsphere Co., Ltd. entered into additional collaborations relating to ATMPs and medical technologies with business partners in order to develop innovations and enhance future medical treatment capabilities.

Overall, these strategic collaborations reflect the Company's expansion of capabilities in both medical technology and partnerships with public and private sector organizations, which serve as important foundations for further business development and sustainable long-term growth.

-Translation -

Section 3 Quality and Service Standards

The Company places significant emphasis on the continuous enhancement of service quality and standards and has obtained both domestic and international certifications, including the Health Establishment License, ISO 15189 and ISO 15190 standards for medical laboratories, as well as ISO/IEC 27001 certification for information security management systems.

In addition, the Company has successfully passed quality assessments and proficiency testing conducted by international organizations and government agencies in several areas, including GenQA for NIPT testing, QCMD SARS-CoV-2 External Quality Assessment (EQA), and proficiency testing programs administered by the Department of Medical Sciences for HPV DNA testing, BRCA1/BRCA2 testing, and various infectious disease diagnostics, in order to validate the accuracy and reliability of its testing and analytical results.

With respect to sustainable business operations, the Company conducts its business in accordance with ESG principles and has obtained Carbon Footprint for Organization (CFO) certification. The Company also continues to develop medical innovations and technologies, resulting in its receipt of the “The Most Innovative” award from the Future Trends Awards 2026.

Section 4 Vision and Business Strategies for 2026

The Company positions itself as an accessible premium healthcare service provider driven by innovation, with a focus on delivering integrated healthcare solutions throughout all stages of life, ranging from prevention, screening, and diagnosis to long-term healthcare management.

The Company envisions becoming a leader in innovative healthcare systems by applying genomics and Precision Medicine technologies to enhance healthcare services with greater accuracy and comprehensive coverage across all age groups. The Company is also committed to delivering internationally recognized healthcare innovations through Genomics technologies and Advanced Therapy Medicinal Products (ATMPs) to support preventive healthcare, rapid disease diagnosis, and more effective personalized treatment.

In addition, the Company aims to develop a comprehensive Healthcare Ecosystem using genomic data as a key foundation to transform healthcare delivery from a treatment-based approach toward prevention, screening, and precision healthcare in the future.

For the Company’s business strategies for 2026, which are focused on achieving sustainable organizational growth, the Company has established four key strategies as follows:

1. Integrated Growth Strategy

The Company aims to create a balanced expansion of services across both the public and private sectors through various forms of partnerships, such as the execution of Memoranda of Understanding (MOUs), the establishment of joint operation centers and laboratories, the distribution of equipment, and the co-development of service platforms, in order to support high-quality and sustainable growth.

2. Education & Awareness Strategy

The Company places importance on promoting knowledge and awareness relating to Genomics and Precision Medicine through seminars, webinars, and various communication channels in order to foster

-Translation -

accurate understanding, build confidence, and support access to healthcare information among the public and medical professionals.

3. Partnership Expansion Strategy

The Company aims to expand collaborations at both the national and regional levels in order to enhance access to services, elevate service standards, and strengthen networks in the fields of medical services and technology.

4. Digital Transformation Strategy

The Company is committed to developing comprehensive end-to-end digital systems to integrate all operational processes, reduce redundancies, improve operational efficiency, and enhance the experience of service recipients and medical professionals.

These four strategic pillars will work collectively to support sustainable growth and drive the Company toward becoming a leader in Precision Healthcare and innovative healthcare systems in the future.

Section 5 The Company's Core Technologies

The Company's core technologies (Key Technology Driving Products) encompass DNA, RNA, Proteomics, Cell Omics, Epigenomics, and Radiomics technologies to support the development of products and services in the field of Precision Healthcare.

The Company possesses comprehensive technological capabilities covering the entire process, ranging from biological data reading and analysis technologies (Reading Technology), sample and data storage systems (Storage), to platform development and practical applications (Application). These capabilities can support utilization in medical services, research, public health, agriculture, and the life sciences industry.

In addition, the Company places importance on Epigenomics technology, which involves the study of gene expression that can change according to age, behavior, and environmental factors, in order to support preventive healthcare and long-term health monitoring. Overall, these technologies reflect the Company's Technology Ecosystem, which serves as a key foundation for the development of Precision Healthcare and comprehensive precision health management.

The Chairman then opened the session for shareholders to ask questions or comments.

In this regard, shareholders raised certain questions, which the directors and management will address during the "Q&A" session at the end of the meeting, including clarifications relating to the Management Discussion and Analysis (MD&A).

As this agenda item was for acknowledgment only, no voting was required from the shareholders. The meeting therefore acknowledged the Company's operating results for the year 2025.

-Translation -

Agenda 4 To consider and approve the financial statements for the year ended 31 December 2025

The Chairman informed the meeting that, pursuant to Section 112 of the Public Limited Companies Act B.E. 2535 (1992) (as amended) (the “Public Limited Companies Act”) and Article 55 of the Company’s Articles of Association, the Board of Directors is required to prepare the balance sheet and profit and loss statement as of the end of the Company’s fiscal year and submit them to the Annual General Meeting of Shareholders for consideration and approval. The Board of Directors must also arrange for the financial statements to be audited by the auditor prior to submission to the shareholders’ meeting.

The Company has therefore prepared the financial statements for the year 2025 ended 31 December 2025, the details of which are set out in Part 3: Financial Statements of the Annual Report (Form 56-1 One Report), which has been delivered to the shareholders and published on the Company’s website. The summary of the key information is as follows:

(Unit:Million Baht)

Items	Consolidated Financial Statements		Separate Financial Statements	
	2025 (Proposed Year)	2024	2025 (Proposed Year)	2024
Total Assets	701.86	607.59	691.57	605.75
Total Liabilities	148.71	68.44	141.80	68.40
Shareholders’ Equity	553.15	539.15	549.77	537.35
Paid-up Capital	300.00	300.00	300.00	300.00
Total Revenue	386.73	345.87	377.24	345.87
Net Profit	45.33	50.16	43.74	50.32
Basic Earnings Per Share (Baht/Share)	0.08	0.09	0.07	0.09

The Company’s financial statements for the year ended December 31, 2024, have been audited and certified by the Company’s auditor, Dr.Virach & Associates Office Co., Ltd. The financial statements have also been reviewed by the Audit Committee and approved by the Board of Directors’ meeting held on February 25, 2026.

The Chairman then opened the session for shareholders to ask questions or comments.

There were no questions or comments from the shareholders.

The Chairman therefore requested the meeting to consider and approve the financial statements for the year ended 31 December 2025

Meeting Resolution The meeting, by a majority vote of the shareholders present at the meeting and casting their votes, approved the financial statements for the year ended 31 December 2024, with the following voting results:

Approve	436,599,201 votes or 99.99999954%
Disapprove	2 votes or 0.00000046%
Abstain	0 votes

-Translation -

Agenda 5 To consider and approve the allocation of the net profit as a legal reserve and dividend Payment

The Chairman informed the meeting that, pursuant to Section 116 of the Public Limited Companies Act and Article 50 of the Company's Articles of Association, the Company is required to allocate a portion of its annual net profit as a legal reserve in an amount of not less than five percent (5%) of the annual net profit, less any accumulated losses brought forward (if any), until such reserve reaches an amount of not less than ten percent (10%) of the Company's registered capital.

The Company also has a policy to pay dividends to shareholders at a rate of not less than 40% of the net profit from the Company's separate financial statements after deduction of corporate income tax and allocation to the legal reserve. However, the Company may consider paying dividends at a rate different from the stated policy depending on the operating results, financial position, liquidity, working capital requirements, business management, future business expansion plans, and overall economic conditions.

Based on the Company's operating results, it was proposed that the 2026 Annual General Meeting of Shareholders consider and approve the allocation of the 2025 net profit in the amount of THB 2.2 million as a legal reserve, representing not less than 5% of the Company's net profit. Following such allocation, the Company's total legal reserve will amount to THB 13.2 million.

In addition, it was proposed that the meeting consider and approve the dividend payment for the operating results of the year 2025 at the rate of THB 0.05 per share for 600,000,000 ordinary shares, totaling THB 30 million, representing 68.59% of the Company's net profit according to the Company's separate financial statements. Such dividend payment is in accordance with the Company's dividend payment policy as mentioned above.

In this regard, the Company has fixed the Record Date for shareholders entitled to receive dividends on 7 May 2026, and the dividend payment date has been scheduled for 28 May 2026.

The Chairman then opened the session for shareholders to ask questions or comments.

There were no questions or comments from the shareholders.

The Chairman requested the meeting to consider and approve the allocation of net profit as a legal reserve and the dividend payment for the operating results of the year 2025.

Meeting Resolution The meeting resolved, by a majority vote of the shareholders present and casting their votes, to approve the allocation of net profit as a legal reserve and the dividend payment for the operating results of the year 2025, with the following details:

1. Approved the allocation of the 2025 net profit in the amount of THB 2.2 million as a legal reserve, representing not less than 5% of the Company's net profit. Approved the dividend payment for the operating results of the year 2025 at the rate of THB 0.05 per share, totaling THB 30 million.

2. In this regard, the Company fixed the Record Date for shareholders entitled to receive dividends on 7 May 2026, and scheduled the dividend payment date for 28 May 2026. with the following voting results:

-Translation -

Approve	436,599,203 votes or 100%
Disapprove	0 votes or 0%
Abstain	0 votes

Agenda 6 To consider and approve the directors' remuneration for the year 2026

The Chairman informed the meeting that, pursuant to Section 90 of the Public Limited Companies Act, the payment of directors' remuneration shall be in accordance with the Company's Articles of Association and approved by a resolution of the shareholders' meeting with votes of not less than two-thirds (2/3) of the total votes of the shareholders present at the meeting.

In addition, Article 33 of the Company's Articles of Association provides that directors are entitled to receive remuneration from the Company in the form of rewards, meeting allowances, gratuities, bonuses, or other forms of benefits in accordance with the Articles of Association or as determined by the shareholders' meeting. Such remuneration may be fixed as a definite amount or prescribed according to certain criteria, and may be determined from time to time or remain effective until amended. Directors are also entitled to receive allowances and welfare benefits in accordance with the Company's regulations.

After due consideration and screening by the Executive Committee, the criteria for determining directors' remuneration were reviewed by taking into account the appropriateness of the remuneration in comparison with listed companies in the same industry, as well as the Company's operating results, business size, responsibilities of the Board of Directors, and net profit. Accordingly, it was deemed appropriate to propose that all categories of directors' remuneration remain unchanged from those approved for the year 2025, with details as follows:

Monthly Remuneration of the Board of Directors (Baht/person)

Position	2026	2025	Change from 2025
Chairman of the Board	50,000 บาท	50,000 บาท	-
Directors	40,000 บาท	40,000 บาท	-

Meeting Allowance for Sub-committees. (Audit Committee and Executive Committee) (Baht/person/time)

Position	2026	2025	Change from 2025
Chairman of the Board	20,000 บาท	20,000 บาท	-
Directors	15,000 บาท	15,000 บาท	-

Furthermore, directors who hold executive positions in the Company will receive compensation solely in their capacity as executives and will not receive any compensation in their capacity as directors. (Chief Executive Officer and Deputy Chief Executive Officer)

In this regard, the Board of Directors deemed it appropriate to propose that the shareholders' meeting consider and approve the payment of a bonus to the Board of Directors at the rate of 5% of the net profit for the year 2026.

-Translation -

The Chairman then opened the session for shareholders to ask questions or comments.

There were no questions or comments from the shareholders.

The Chairman therefore requested the meeting to consider and approve the directors' remuneration for the year 2026.

Meeting Resolution The meeting, by not less than two-thirds of the total number of votes of the shareholders present at the meeting, approved the directors' remuneration for the year 2025 as follows:

Monthly Remuneration of the Board of Directors (Baht/person)

1. Chairman of the Board 50,000 Baht per month
2. Directors 40,000 Baht per month

Meeting Allowance for Sub-committees. (Audit Committee and Executive Committee) (Baht/person/time)

1. Chairman of the Board 20,000 Baht per time
2. Directors 15,000 Baht per time

Furthermore, directors who hold executive positions in the Company will receive compensation solely in their capacity as executives and will not receive any compensation in their capacity as directors. (Chief Executive Officer and Deputy Chief Executive Officer)

The Board of Directors has proposed to the meeting for consideration and approval the payment of bonuses to the Board of Directors at a rate of 5% of the net profit from the Company's operating results for the year 2026 (ended 31 December 2026). with the following voting results:

Approve	436,599,203 votes or 100%
Disapprove	0 votes or 0%
Abstain	0 votes

Agenda 7 To consider and approve the appointment of directors in replacement of those who must retire by rotation

For this agenda item, in order to ensure transparency, fairness, and compliance with good corporate governance principles, the following 4 (four) directors who are due to retire by rotation and are considered interested persons in this matter were requested to temporarily leave the meeting until the consideration of this agenda item had been completed: 1. Mr. Goanpot Asvinvichit

2. Mr. Preecha Laohapongchana
3. Dr. Saowalak Dansakul
4. Mr. Xiaohan Wang

After the four directors had left the meeting, the meeting proceeded to consider this agenda.

The Chairman informed the meeting that, pursuant to Section 71 of the Public Limited Companies Act and Article 18 of the Company's Articles of Association, at every Annual General Meeting of Shareholders,

-Translation -

one-third (1/3) of the directors shall retire by rotation. If the number of directors cannot be divided into three equal parts, the number nearest to one-third (1/3) shall retire.

For the first and second years following the registration of the Company, the directors to retire shall be determined by drawing lots. In subsequent years, the directors who have held office for the longest period shall retire from office. Directors retiring by rotation may be re-elected.

At present, the Company has a total of 11 directors. At the 2026 Annual General Meeting of Shareholders, 4 directors are due to retire by rotation as follows:

- | | | |
|-----------------|----------------|---|
| 1. Mr. Goanpot | Asvinvichit | Chairman of the Executive Committee |
| 2. Mr. Preecha | Laohapongchana | Executive Director |
| 3. Dr. Saowalak | Dansakul | Director / Chief Executive Officer |
| 4. Mr. Xiaohan | Wang | Director / Deputy Chief Executive Officer |

The Board of Directors, excluding the interested directors, considered and deemed it appropriate to propose to the 2026 Annual General Meeting of Shareholders the re-election of all four directors who are due to retire by rotation to continue serving as directors for another term.

In this regard, the Company has enclosed the brief profiles of the nominated persons together with the notice of the shareholders' meeting.

The Chairman then opened the session for shareholders to ask questions or comments.

There were no questions or comments from the shareholders.

The Chairman requested the meeting to consider and approve the appointment of directors to replace those retiring by rotation.

Meeting Resolution The meeting, by a majority vote of the shareholders present at the meeting and casting their votes, approved the election of 4 directors to replace those who retired by rotation, with the following voting results:

- | | | |
|-----------------|----------------|-------------------------------------|
| 1. Mr. Goanpot | Asvinvichit | Chairman of the Executive Committee |
| Approve | 436,599,203 | votes or 100% |
| Disapprove | 0 | votes or 0% |
| Abstain | 0 | votes |
| 2. Mr. Preecha | Laohapongchana | Executive Director |
| Approve | 436,599,203 | votes or 100% |
| Disapprove | 0 | votes or 0% |
| Abstain | 0 | votes |
| 3. Dr. Saowalak | Dansakul | Director / Chief Executive Officer |
| Approve | 436,599,203 | votes or 100% |
| Disapprove | 0 | votes or 0% |
| Abstain | 0 | votes |

-Translation -

4. Mr. Xiaohan Wang	Director / Deputy Chief Executive Officer
Approve	436,599,203 votes or 100%
Disapprove	0 votes or 0%
Abstain	0 votes

Upon completion of the voting for this agenda item, the Chairman invited the four directors to return to the meeting to participate in the consideration of the subsequent agenda items.

Agenda 8 To consider and approve the appointment of auditor and fix his/her remuneration for the year 2026

The Chairman informed the meeting that, in accordance with Section 120 of the Public Limited Companies Act B.E. 2535 (1992) and Articles 58 and 59 of the Company's Articles of Association, the Annual General Meeting of Shareholders is required to appoint the Company's auditor and determine the audit fee each year.

Thus, the 2026 Annual General Meeting of Shareholders of the Company is required to appoint the auditor and determine the auditors' fee for the year 2026. In selecting a qualified auditor with reasonable audit fees for the fiscal year 2026, the Audit Committee has recommended that the 2026 Annual General Meeting of Shareholders appoint an auditor from Dr. Virach & Associates Office Co., Ltd. as the Company's auditors for the year 2026. The proposed auditors are as follows:

1. Dr. Virach Aphimeteetamrong Certified Public Accountant No. 1378 and/or
2. Mr. Chaiyakorn Aunpitipongsa Certified Public Accountant No. 3196, and/or
3. Mr. Apiruk Ati-anuwat Certified Public Accountant No. 5202

and to approve the audit fee for the year 2026 for the Company in the amount of THB 1,890,000, representing an increase of THB 60,000 from the previous year. The increase was due to the Company's investment and business expansion, including its subsidiaries and associated companies, which resulted in additional workload for the audit of the annual consolidated financial statements and quarterly consolidated financial statements. Accordingly, the audit fee for 2026 was adjusted appropriately.

The aforementioned remuneration consists of:

- Annual audit fee for the Company's separate financial statements: THB 960,000
- Quarterly review fees: THB 660,000
- Audit fee for Board of Investment (BOI) reporting information: THB 50,000
- Annual audit fee for consolidated financial statements: THB 70,000
- Quarterly review fees for consolidated financial statements: THB 150,000

The three nominated auditors possess qualifications in accordance with the regulations of the Securities and Exchange Commission regarding auditor rotation, namely that none of them has performed audit or review duties and expressed opinions on the Company's financial statements for five consecutive fiscal years.

-Translation -

In addition, Dr. Virach & Associates Office Co., Ltd. and the aforementioned auditors have no relationship or conflict of interest with the Company, its management, major shareholders, or related persons of such individuals.

The Chairman then opened the session for shareholders to ask questions or comments.

There were no questions or comments from the shareholders.

The Chairman therefore requested the meeting to consider and approve the appointment of auditor and fix his/her remuneration for the year 2026.

Meeting Resolution The meeting, by a majority vote of the shareholders present at the meeting and casting their votes, approved the appointment of auditor and fix his/her remuneration for the year 2026, as follows:

1. Approved to appoint the auditors from Dr. Virach & Associates Office Co., Ltd., namely;

1. Dr. Virach Aphimeteetamrong Certified Public Accountant No. 1378 and/or
2. Mr. Chaiyakorn Aunpitipongsa Certified Public Accountant No. 3196, and/or
3. Mr. Apiruk Ati-anuwat Certified Public Accountant No. 5202

to serve as the auditor of the Company and to express his opinion on the financial statements of the Company.

2. Approved the audit fee for 2026 in the amount of 1,890,000 Baht.

with the following voting results:

Approve	436,599,203 votes or 100%
Disapprove	0 votes or 0%
Abstain	0 votes

Agenda 9 Others (if any)

The Chairman informed the meeting that, according to Section 105 of the Public Limited Companies Act B.E. 2535 (1992), it is stated that “Shareholders holding not less than one-third (1/3) of the total number of issued shares may request the meeting to consider other matters in addition to those specified in the notice of the meeting.” As no shareholders proposed any additional agenda items, there would be no additional matters presented for the meeting’s consideration, and no resolution would be made under this agenda.

The Chairman then invited the shareholders to raise questions and/or provide useful suggestions to the Board of Directors and/or to allow the directors and management to clarify any inquiries or concerns relating to the Company under the “Q&A” session, including clarifications relating to the Management Discussion and Analysis (MD&A).

-Translation -

In this regard, shareholders raised various questions and comments, which may be summarized as follows:

Question No. 1

Ms. Chanathip Wittayakool, a volunteer shareholder rights protector (proxy holder from the Thai Investors Association)

According to the 56-1 One Report on page 70, the average collection period increased significantly from 56.22 days in 2024 to 109.81 days in 2025. The near doubling of the collection period directly affects operating cash flow and may increase the risk of expected credit loss provisions in the event of customer default.

The shareholder therefore inquired whether the increase in the collection period was attributable to extended payment terms from government sector customers, and what measures the Company has implemented to manage and monitor outstanding receivables in order to maintain appropriate liquidity.

Mr. Kittikun Rodrangnok, Chief Financial Officer responded to Question No. 1

The Chief Financial Officer responded that the increase in the average collection period from 56.22 days in 2024 to 109.81 days in 2025 reflected the Company's success in expanding its market in line with its strategic plan, particularly the expansion of its customer base to hospitals and government agencies through the reagent placement business model. Although government sector customers generally have longer payment processes than private sector customers due to governmental disbursement procedures, such customers are considered financially stable and carry low credit risk.

The Company continues to maintain an appropriate financial position and liquidity level, with a debt-to-equity (D/E) ratio of 0.27 times and a current ratio of 4.58 times, reflecting the Company's effective cash flow management and ability to support business expansion efficiently. In addition, the Company has a dedicated credit management team responsible for monitoring payment status and closely coordinating with government agencies to ensure collections are in line with disbursement cycles and to minimize the risk of expected credit loss provisions.

Question No. 2

Ms. Chanathip Wittayakool, a volunteer shareholder rights protector (proxy holder from the Thai Investors Association)

According to the MD&A report, government policies implemented by the National Health Security Office (NHSO), which provide free screening services at public healthcare facilities, together with the declining birth rate, have affected the Company's core revenue in the reproductive health segment (NIFTY). The Company's traditional core business is therefore facing growth limitations and potentially lower profit margins due to increasing price competition.

-Translation -

The shareholder therefore inquired about the Company's plans to launch genomics testing services in other areas, such as cancer and rare diseases, in order to create new growth drivers (New S-Curve) to replace declining revenue streams and support the recovery and future growth of net profit in line with the Company's targets.

Dr.Saowalak Dansakul, Chief Executive Officer responded to Question No. 2

Management recognizes the challenges facing the Company's traditional business, particularly in the reproductive health segment, which has been affected by intensifying competition, demographic changes, and government policies supporting certain screening services in public healthcare facilities. Nevertheless, the Company has continuously adjusted its business strategies, including expanding its customer base among public hospitals, large-scale hospitals, and business partners, in order to maintain competitiveness and create long-term growth opportunities.

To create new growth drivers (New S-Curve), the Company is focusing on expanding genomics services with strong future growth potential, such as rare disease diagnostics, for which the government has increasingly placed importance on and provided support for genetic testing. The Company is also expanding into the oncology business, particularly cancer diagnostics, which is considered a high-growth market both in Thailand and internationally. In this regard, in 2026 the Company plans to establish its own oncology laboratory in Thailand in order to transition from being a testing referral provider to becoming a fully integrated service provider. This will enhance cost management efficiency, reduce service turnaround time, and support the growing demand for cancer screening, diagnosis, and treatment through Precision Medicine technologies, which are expected to continue expanding in the future.

In addition, the Company places significant emphasis on the Advanced Therapy Medicinal Products (ATMPs) business, which represents a medical innovation with strong global growth potential. The Company has already begun laying the foundation through investments, technology development, and collaborations with business partners and relevant organizations to support the advancement of personalized medicine and modern therapeutic technologies. These initiatives are expected to become key drivers supporting the Company's long-term revenue growth and profitability.

Question No. 3

Kamolchai Charatcharoenjongkul (The investor submitted questions in advance through the Investor Relations department.)

From the Company's operating results in the fourth quarter of 2025, during which the Company achieved a significantly improved net profit of approximately THB 26 million, together with the strong growth in revenue from the laboratory products segment (Lab Products), the investor inquired whether such supporting factors were merely attributable to short-term delivery cycles and revenue recognition, or whether they would represent sustainable momentum capable of maintaining continuous growth throughout 2026.

-Translation -

Mr.Kittikun Rodrangnok, Chief Financial Officer responded to Question No. 3

The significant improvement in operating performance during the fourth quarter of 2025 was not merely attributable to short-term revenue recognition, but rather resulted from a recurring income structure arising from the strategies that the Company had implemented since the second and third quarters of the previous year. Accordingly, the Company views this trend as an important factor supporting continuous growth throughout 2026, with two principal supporting factors as follows:

The first supporting factor is that the Company has been able to further expand its market penetration into government agencies and large private hospital groups. These hospitals generally have relatively high testing volumes, resulting in continuous growth in reagent usage and diagnostic testing services on a monthly basis. The Company continues to see sustained growth potential from this customer segment in the periods ahead.

The second supporting factor is that the Company is not focusing solely on its traditional business operations, but is also continuously expanding into new services. This includes the establishment of the Company's own oncology laboratory to support the growing demand for cancer screening and treatment services. Such expansion will enable the Company to manage testing costs more efficiently and is expected to positively contribute to profit margins in the future.

In addition, projects relating to Advanced Therapy Medicinal Products (ATMPs) and other new initiatives for which the Company laid the foundation and invested in development during the previous year are expected to gradually begin generating revenue from 2026 onward. The Company believes that these projects will become another key factor supporting long-term revenue growth and profitability. The Company therefore remains confident in the business growth outlook, supported by both its stable recurring income base and the opportunities arising from new businesses with strong future growth potential.

Question No. 4

Kamolchai Charatcharoenjongkul (The investor submitted questions in advance through the Investor Relations department.)

How does the Company assess the overall operating performance outlook for the first quarter of 2026, particularly when compared with the relatively high base achieved in the fourth quarter of 2025? In addition, does demand for screening tests and related services continue to meet the Company's targets as planned?

Mr.Kittikun Rodrangnok, Chief Financial Officer responded to Question No. 4

Although the Company recorded a high revenue base in the fourth quarter of 2025, the growth outlook continues to align with the Company's strategic plans. This is because the Company had already laid the foundation for its business strategies since the second and third quarters of the previous year, resulting in continued growth momentum into 2026.

-Translation -

Accordingly, the operating performance for the first quarter of 2026 remains in line with the Company's targets. The majority of the revenue growth has been derived from recurring income generated through the expansion of medical equipment installations in laboratories, which has led to continuous demand for testing reagents and consumable materials.

In addition, the Company has expanded its customer base to include public hospitals and large-scale hospitals with high testing volumes and consistent demand for services. At the same time, the Company has gradually begun recognizing revenue from new services and projects for which investments and preparations had already been made in prior periods.

Question No. 5

Mr. Chokechai Skulwisit (Shareholder)

Referring to the Chairman's statement that the analytical testing systems have continuously improved in accuracy, the investor inquired as to what are the key factors contributing to such accuracy improvements, and what factors are important for the Company in creating a competitive cost advantage in genetic and genomics testing services.

Dr.Saowalak Dansakul, Chief Executive Officer responded to Question No. 5

The key factor contributing to the accuracy of genetic and genomics testing systems is the genetic database. The larger the amount of accumulated data and sample information the Company possesses, the greater the efficiency in analyzing and interpreting genetic information. This enables the Company to continuously improve the accuracy of disease diagnosis and testing outcomes. At the same time, the increase in testing volume also allows the Company to achieve better cost management and improve cost efficiency on a per-unit basis.

In addition, artificial intelligence (AI) technology plays an increasingly important role in genetic data analysis, particularly in the process of variant calling, which enhances both the speed and accuracy of diagnostic testing. AI also supports the Company's long-term development of Precision Medicine technologies.

In this regard, the Company's collaboration with business partners, including BGI, is another key factor that strengthens the Company's competitive capabilities in areas such as research and development, technology transfer, cost support, and access to efficient technologies. These collaborations help enhance the Company's cost competitiveness and continuously support the development of its analytical testing systems.

-Translation -

Question No. 6

Mr. Rakkiat Thaiaporn (Shareholder)

If considering the significant revenue growth achieved in the fourth quarter of 2025, what proportion of such revenue is considered recurring income that is expected to continue into subsequent quarters?

Mr.Kittikun Rodrangnok, Chief Financial Officer responded to Question No. 6

The revenue growth achieved in the fourth quarter of 2025 was largely derived from recurring income that is expected to continue into subsequent quarters. At present, the Company estimates that approximately 60% of its revenue is generated from recurring service-related income and ongoing projects, while the remaining 40% is derived from the sale of products and equipment.

In this regard, the Company aims to further increase the proportion of recurring income businesses in order to strengthen the stability and sustainability of its long-term revenue structure. The Company expects that, in the future, the revenue mix may gradually adjust toward an approximate 50:50 ratio between recurring service income and product sales revenue, which would support a more balanced and stable revenue structure.

Question No. 7

Mr. Torpong Krongtriwet (Shareholder)

What types of businesses or products generate revenue from Advanced Therapy Medicinal Products (ATMPs)?

Mr.Kittikun Rodrangnok, Chief Financial Officer responded to Question No. 7

Revenue from Advanced Therapy Medicinal Products (ATMPs) is primarily generated from modern medical businesses that utilize cells, tissues, and advanced biotechnology in disease treatment, which differs from conventional treatments using traditional chemical-based pharmaceuticals. At present, the Company has collaborations with several universities and medical partners in the development and provision of Cell Therapy services, particularly for the treatment of blood cancers and bone marrow cancers.

In this regard, the Company expects to begin recognizing revenue from the ATMPs business more significantly from the fourth quarter of 2026 onward. The Company views this business segment as another important driver supporting future revenue growth and profitability.

-Translation -

Question No. 8

Mr. Vichit lao-asathiankul (Shareholder)

After the expiration of the BOI tax privileges, what corporate income tax rate will the Company be subject to, and how is this expected to affect the Company's operating results?

Mr. Kittikun Rodrangnok, Chief Financial Officer responded to Question No. 8

The Company places continuous importance on tax management and the preservation of shareholders' benefits. Although the Company's original Board of Investment (BOI) tax privileges have already expired, the Company has now successfully obtained approval for a new BOI promotion certificate, which will allow the Company to continue receiving tax privileges from 2026 to 2034.

These privileges will support the Company's business operations, investments, and long-term growth planning, as well as help mitigate the impact of corporate income tax expenses while continuously supporting the Company's profitability and cash flow. Accordingly, the Company remains confident in its business direction and its ability to generate appropriate long-term returns for shareholders.

The Chief Executive Officer expressed appreciation to all shareholders, proxy holders, representatives from the Thai Investors Association, and all relevant parties for taking the time to attend the meeting. She assured all shareholders that the Company is well-prepared, with concrete business plans in place, and is committed to ensuring long-term stability, sustainability, and continued growth in line with the Company's strategic direction, both in terms of business performance and the advancement of Thailand's public health sector.

The Chairman of the meeting then thanked all shareholders for their attendance and formally declared the meeting closed.

The meeting was adjourned at 12:13 p.m.

Dr. Thosaporn Sirisumphand
Chairman of the meeting

-Translation -

Attachment

Summary of Questions, Answers, and Recommendations from the 2026 Annual General Meeting of Shareholders Clarifications Relating to the Management Discussion and Analysis (MD&A)

Question No. 9

Mr. Vichit lao-asathiankul (Shareholder)

As the Company has adjusted its revenue mix by increasing the proportion of revenue from the sale of medical supplies and equipment, the shareholder requested information regarding the market size of such business, the approximate gross profit margin, as well as the stability and continuity of the supply of related products and equipment.

Mr. Kittikun Rodrangnok, Chief Financial Officer responded to Question No. 9

The Company has adopted a strategy to diversify its revenue structure by increasing the proportion of revenue derived from the sale of laboratory instruments, reagents, and medical solutions, alongside its genetic and genomics testing service business. This strategy is in line with the continued growth trends in the precision medicine and modern laboratory industries.

In 2025, revenue from the sale of laboratory instruments and reagents amounted to approximately THB 100.77 million, representing approximately 26.55% of total operating revenue, an increase from 23.73% in 2024, reflecting significant growth in this business segment.

Regarding market size, the Company views the market for medical diagnostic instruments and reagents, particularly in the areas of Next Generation Sequencing (NGS), Precision Medicine, and Molecular Diagnostics, as having strong growth potential. This is driven by the expansion of preventive disease screening, the transition toward an aging society, government support initiatives such as programs by the National Health Security Office (NHSO), and the increasing adoption of genomics technologies within the healthcare system.

In terms of profitability, the Company focuses on distributing products related to analytical testing platforms in which the Company possesses expertise. This enables the Company to effectively manage costs and generate recurring revenue from the sale of reagents and consumable materials. In 2025, the product distribution business achieved a gross profit margin of approximately 43.73%

With respect to supply stability, the Company maintains collaborations with the BGI Group and international medical technology partners, while also carefully selecting reliable and certified suppliers to ensure the continuous and high-quality supply of instruments, reagents, and related equipment.

-Translation -

Question No. 10

Mr. Vichit lao-asathiankul (Shareholder)

In cases where the Company increasingly distributes equipment and instruments to customers, which may enable customers to conduct analytical testing on their own, what strategies or management approaches does the Company have in place to maintain revenue from its service business?

Mr.Kittikun Rodrangnok, Chief Financial Officer responded to Question No. 10

The Company views the distribution of instruments and the provision of analytical testing services as complementary businesses rather than competing businesses. Many customers continue to rely on the Company's expertise in bioinformatics, quality control, advanced data analysis, and highly specialized testing services, which still require the Company's laboratories and professional teams.

In addition, the Company has established strategies to generate recurring revenue through the sale of reagents and consumable materials, maintenance and technical support services, bioinformatics analysis services, and specialized testing services utilizing advanced technologies.

Accordingly, the Company believes that expanding its instrument distribution business will help broaden its customer base and create a business ecosystem that supports the long-term growth of service-related revenue.

Question No. 11

Mr. Rakkiat Thaiaporn (Shareholder)

The significant increase in outstanding receivables aged between 3–6 months was primarily attributable to receivables from government agencies or private sector customers, and the shareholder inquired about the likelihood of collection as well as the Company's approach to managing such receivables.

Mr.Kittikun Rodrangnok, Chief Financial Officer responded to Question No. 11

Further to the response provided for Question No. 1, the increase in outstanding receivables aged between 3–6 months primarily relates to receivables from government agencies and large hospitals, resulting from the expansion of the Company's customer base in line with its strategic plan through the reagent placement business model. Although government agencies generally have longer disbursement processes than private sector customers due to governmental procedures, such customers are considered financially stable and carry low credit risk.

In this regard, the Company continues to receive payments in accordance with the disbursement cycles of government agencies. The Company also has a dedicated credit management team responsible for closely monitoring payment status and coordinating with customers in order to effectively manage liquidity and minimize the risk of bad debts.

-Translation -

Question No. 12

Mr. Rakkiat Thaiaporn (Shareholder)

What were the reasons for the Company establishing an additional 3–4 subsidiaries and associated companies, and what are the growth prospects of each company over the next three years?

Mr.Kittikun Rodrangnok, Chief Financial Officer responded to Question No. 12

The establishment of additional subsidiaries and associated companies was intended to support the future expansion and development of the Company’s healthcare, medical technology, and advanced therapy medicinal products businesses, as well as to prepare for joint investments and collaborations with new business partners or investors under the structure of each subsidiary.

With respect to Omicsphere Co., Ltd., the company currently operates a business involving the retail and wholesale distribution of laboratory instruments, equipment, raw materials, chemicals, and scientific supplies used in laboratories. The Company has increased the capital of Omicsphere Co., Ltd. to support the expansion of its Advanced Therapy Medicinal Products (ATMPs) business, including the development of related platforms and information technology systems for service operations and reporting systems. Such initiatives commenced in the fourth quarter of 2025, and clearer operating results are expected to become evident from 2026 onward.

As for Biovision Co., Ltd., the company is currently undergoing internal restructuring following changes in its shareholder structure. Its original business structure was intended to focus on business consultancy and management services. Following the restructuring, the Company is currently discussing future business directions and operational plans.

In addition, Comprehensive Care Co., Ltd. has established business plans relating to medical technologies, advanced therapy medicinal products, and equipment associated with cell therapy. At present, new investors have joined the shareholding structure, and the company is in the process of restructuring and preparing its operational plans to support future business expansion and strategic direction. The Company expects to have a clearer operational outlook within 2026.

Question No. 13

Mr. Rakkiat Thaiaporn (Shareholder)

The shareholder commented that the Company’s previous Opportunity Day (“Oppday”) session had received strong interest and was highly beneficial to shareholders and interested investors. The shareholder therefore suggested that the Company consider organizing additional earnings calls in collaboration with the Stock Exchange of Thailand, or at least conduct such sessions twice per year.

Mr.Kittikun Rodrangnok, Chief Financial Officer responded to Question No. 13

Management would like to thank the shareholder for the suggestion and continued interest in following the Company’s information. The Company recognizes the importance of continuously communicating information to shareholders, investors, and interested parties.

-Translation -

In this regard, the Company will take the suggestion regarding the organization of Opportunity Day or Earnings Call sessions into consideration together with the Executive Committee, with the aim of enhancing communication channels and further improving understanding of the Company's operating results and business direction.

Question No. 14

Mr. Torpong Krongtriwet (Shareholder)

1. How does the Company allocate the proportion of NIPT testing samples under the National Health Security Office (NHSO) project among its business partners?

2. What was the total number of NIPT tests conducted by the Company throughout 2025, and how many tests were conducted during the fourth quarter of 2025?

3. In the first quarter of 2026, how many NIPT tests did the Company conduct, and by what percentage did this increase compared to the same period of the previous year?

4. Does the Company expect that its operating results in 2026 will be able to absorb the impact of any potential increase in tax expenses, and what management approaches does the Company have in place in this regard?

Mr. Kittikun Rodrangnok, Chief Financial Officer responded to Question No. 14

1. The Company collaborates with both public and private sector partners in providing NIPT services under projects of the National Health Security Office (NHSO). The allocation of service proportions depends on the scope of work and agreements under each project. In this regard, the Company focuses on maximizing the efficiency of its resources and testing capacity in order to support the continuously increasing testing volume.

2. The Company is unable to disclose the number of NIPT samples tested. However, testing volume has increased significantly as a result of the NHSO's supportive policies, which have improved access to Down syndrome screening services and contributed to economies of scale for the business.

3. The Company is unable to disclose the number of NIPT samples tested. Nevertheless, management continues to observe a growth trend in genetic screening services driven by expanded access to public healthcare services and increasing awareness of preventive healthcare.

4. The Company believes that its business operations will be able to absorb the impact of any potential increase in tax expenses. The Company's management approach includes improving cost efficiency, expanding higher-margin revenue streams, increasing the proportion of recurring income, and investing in technology and automation systems to enhance long-term competitiveness.

-Translation -

Question No. 15

Mr. Chokechai Skulwisit (Shareholder)

1. What is the development of “Omics for All,” how is it related to the Bioinformatics system, and what positive impact will it have on the Company’s competitiveness as a foundation for precision and preventive medicine? What is the current development status and trial timeline?

2. Are the Omics database and informatics system developed from the collection of data generated from past and current genetic and genomics testing considered assets of the Company?

3. In the case of large-scale Omics data, is it necessary to further develop and build advanced analytical systems beyond the current capabilities?

4. It is understood that the Company has adopted an advanced analytical system called Dr.Tom. What positive impact is it expected to have on the growth rate of the customer base? In order for the Dr.Tom system to continuously improve its capabilities, what additional databases need to be developed beyond the current Omics and Bioinformatics databases?

5. With respect to genetic and genomics testing services that have been included in the services provided under the NHSO, what applications are currently likely to be included as public healthcare services in the future?

Mr. Xiaohan Wang, Deputy Chief Executive Officer responded to Question No. 15

From the perspective of the Company’s management and BGI, as the major shareholder and operational supporter, global healthcare trends are shifting toward preventive and precision medicine. Omics, genomics, and bioinformatics technologies are expected to play important roles in the future development of healthcare systems. Accordingly, the Company is committed to continuously developing its technological capabilities, databases, and analytical systems in order to strengthen its competitiveness and support long-term business growth.

1. “Omics for All” represents the Company’s strategic development direction aimed at making genomics and other omics technologies more accessible, cost-effective, and clinically applicable for the Thai population and, in the longer term, for Southeast Asia. This initiative is closely linked with the Company’s bioinformatics systems, as omics data alone has limited value if it cannot be processed, analyzed, interpreted, and translated into medical or preventive healthcare decision-making. Therefore, the project encompasses not only laboratory capabilities, but also data management systems, analytical pipelines, interpretation systems, clinical reporting systems, and quality control frameworks.

Regarding progress, BKGI already possesses laboratory capabilities and commercial experience in reproductive health, oncology, rare diseases, and sequencing services. The next phase involves developing informatics systems that are aligned with local contexts, strengthening analytical validation capabilities, and conducting clinical validation in collaboration with domestic partners. The implementation will be carried out gradually rather than through a single large-scale launch. For certain applications, the Company expects development and clinical validation processes to continue progressively over the coming years,

-Translation -

depending on legal requirements, laboratory regulations, collaboration between public and private sector partners, and government reimbursement systems.

2. The Company considers properly collected omics databases, obtained with appropriate ethical and legal consent and maintained under suitable governance frameworks, together with informatics systems and interpretation expertise, to be strategic assets of the Company.

The true value of these assets does not lie solely in the raw data itself, but rather in the integration of data quality, linkage with clinical information, relevance to the Thai population, bioinformatics pipelines, interpretation rules, expert review processes, and accumulated operational experience. These capabilities can enhance analytical accuracy, reduce interpretation turnaround time, support the development of new products, facilitate collaborative clinical research, and strengthen future precision medicine services. However, such assets must remain subject to strict frameworks relating to data privacy, ethics, cybersecurity, and applicable legal and regulatory requirements.

3. The current systems may be sufficient for disease-specific testing services or certain application-specific uses. However, as omics databases continue to expand in scale, more sophisticated and advanced systems will become necessary. As the volume of data increases, the Company aims to further enhance system capabilities in areas such as

- Multi-omics data integration
- Automated variant annotation systems
- AI-assisted interpretation
- Genotype–phenotype correlation
- Longitudinal health data analysis
- Disease risk prediction
- Continuous variant reclassification
- More robust clinical decision support systems

These capabilities are considered critically important as the industry evolves from disease diagnosis toward prevention, early screening, and personalized intervention.

4. Dr.Tom is expected to enhance scalability by making the interpretation process more standardized and efficient. For customers, particularly hospitals and physicians, the key value lies not only in sequencing itself, but in receiving reliable and easy-to-understand reports.

An advanced interpretation platform can help reduce turnaround time, improve consistency of analytical results, support more complex test menus, lower interpretation costs per unit, and enable physicians to integrate genomic testing more easily into routine clinical practice.

The continued development of Dr.Tom requires several supporting infrastructures, including:

- Reference databases for Thai and Southeast Asian populations
- Disease-specific variant databases, such as those relating to cancer, rare diseases, thalassemia, and pharmacogenomics

-Translation -

- Phenotype and outcome databases operated under appropriate consent and governance frameworks
- Drug response and treatment outcome databases
- Multi-omics databases, including genomics, transcriptomics, proteomics, metabolomics, and microbiome data
- Continuous updates of scientific literature, treatment guidelines, and variant knowledge
- Secure cloud or high-performance computing infrastructure
- Integration with LIMS, hospital workflows, and EMR systems
- Cybersecurity systems, audit trails, quality management, and regulatory compliance frameworks
- User-friendly reporting systems supporting the Thai language for physicians
- Networks of clinical experts in Thailand for review and validation purposes

For the Company, such systems will support the expansion of its customer base by enabling the Company to efficiently serve more hospitals, physicians, and a broader range of testing services without requiring proportional increases in specialized personnel. However, the Company believes that such systems should be developed and utilized as “clinical decision support” tools to assist physicians and medical specialists in clinical decision-making, rather than replacing the role of physicians in diagnosing or treating patients.

5. At present, certain genetic and genomic testing services have already begun to be incorporated into the public healthcare system. The Company believes that, in the future, there may be consideration for expanding additional services in areas such as hereditary cancer testing, oncology companion diagnostics, pharmacogenomics testing, rare disease diagnostics, newborn screening, as well as prenatal and reproductive health services.

However, the Company would like to emphasize that these matters currently represent only “potential future trends under consideration,” which will depend on several important factors, including clinical utility, cost-effectiveness, local evidence, budget impact, and public healthcare policy considerations.

The inclusion of such services within healthcare coverage schemes would need to undergo analysis and health economic studies conducted by the relevant government authorities.

As for the Company, its role is to continuously monitor and study industry developments and medical trends, while also preparing its technological capabilities, databases, bioinformatics systems, and service capacity to support future opportunities and the evolving needs of the healthcare system, should there be future policy support or implementation initiatives from the government sector.

Question No. 16

Mr. Chokechai Skulwisit (Shareholder)

What are the trends regarding the expansion of Genomics and Precision Medicine services within Thailand’s National Health Security Office (NHSO) system, and what is management’s perspective on the

-Translation -

future direction of public healthcare policy shifting from reactive treatment toward preventive healthcare and precision medicine?

Dr.Saowalak Dansakul, Chief Executive Officer responded to Question No. 16

Many countries around the world, including Thailand, are increasingly placing importance on preventive and precision medicine in order to improve the efficiency of healthcare systems and reduce long-term healthcare expenditures. The focus is shifting toward prevention, risk screening, and early disease detection, rather than treatment after disease onset.

The Company has continuously observed developments in this trend through the expansion of access to screening and diagnostic services across various areas, including cancer, non-communicable diseases (NCDs), and certain genetic and genomic testing services such as NIPT, BRCA testing, and genetic testing to support personalized treatment planning.

Looking ahead, there may be opportunities for public healthcare policymakers to consider expanding additional services, particularly technologies supported by clinical evidence demonstrating their ability to improve treatment efficiency and reduce long-term healthcare costs. Examples include preventive genetic screening, liquid biopsy, pharmacogenomics, as well as the application of AI and omics data for early risk stratification and screening.

Question No. 17

Mr. Chokechai Skulwisit (Shareholder)

How does the latest development through the collaborative establishment of a Biobank represent a key foundation for precision medicine, and how is it important to the capability of developing and manufacturing ATMP products?

Mr.Kittikun Rodrangnok, Chief Financial Officer responded to Question No. 17

A Biobank is considered a critical infrastructure component for precision medicine, as it serves as a systematic repository for biological samples and related data. Such systems support genomics research, drug development, medical AI development, biomarker discovery, and personalized medicine applications.

For Advanced Therapy Medicinal Products (ATMPs), such as Cell Therapy and Gene Therapy, the establishment of a standardized Biobank enables efficient biological sample management, supports traceability requirements, and facilitates manufacturing processes in accordance with international standards.

Accordingly, the Company views the Biobank as one of the key foundations for expanding its future Precision Medicine and Advanced Therapy businesses.